Neoadjuvant and Adjuvant Immunotherapy

Phase 2Small molecule

Neoadjuvant and Adjuvant Immunotherapy is one of 3 small molecule programs targeting Locally Advanced Head and Neck Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Head and Neck Squamous Cell CarcinomaRecruiting

Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Locally Advanced Head and Neck Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Volrustomig

AstraZeneca

Phase 3

1 2

Neoadjuvant and Adjuvant Immunotherapy

XXiwei XU

Phase 2

1 3

Adjuvant Cisplatin

Radiation Therapy Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07371234

Clinical

Trials by Indication[1]

Locally Advanced Head and Neck Squamous Cell Carcinoma1 trial

A Single Arm, Phase II Clinical Study of Low-Dose Radiotherapy Combined With Anti-PD-1 Monoclonal Antibody Immunotherapy as Neoadjuvant Treatment for Surgically Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting·XXiwei XU·Phase 2·NCT07371234·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neoadjuvant and Adjuvant Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant and Adjuvant Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant and Adjuvant Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiwei XU company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: XXiwei XU

Neoadjuvant and Adjuvant Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Locally Advanced Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News